84P - Clinical characteristics and outcomes of bilateral breast cancer in a Tunisian cohort
|Date||18 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Breast Cancer, Early Stage
Cancer Aetiology, Epidemiology, Prevention
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix19-ix29. 10.1093/annonc/mdw575|
O. Jmour1, A. Belaid1, F. Mghirbi2, F. Benna1
Bilateral breast cancer (BBC) is a particular entity requiring an appropriate care. It can be synchronous or metachronous. The aim of this study was to describe the epidemiological profile, the clinicopathological and therapeutic features of bilateral breast cancer and to evaluate their prognosis and survival.
We have undertaken a monocentric retrospective study of 140 patients with BBC treated and followed at the Salah Azaiez Institute. Cases diagnosed within 6 months of diagnosis of the first breast cancer were classified as synchronous and cases diagnosed more than 6 months were classified as metachronous.
The frequency of BBC was 2.3%. Thirty-nine patients had metachronous cancer and 101 had synchronous one. The mean interval between the first and the second cancer was 13,5 months. The mean age was 49 years. Sixty-two percent were postmenopausal. Fourteen percent had a positive family history for breast carcinoma. Mammography showed opacity with malignant features in the contralateral breast in 46,6% of the cases. The average tumor size was 46 mm. T4 stage was found in 34.4% patients. Twenty-seven patients (19.3%) had metastatic disease at diagnosis. Bilateral surgery was performed in 73,6% whose radical one was done in 53.6% of the cases. On pathology, ductal invasive carcinoma was found in 79,3% of cases whereas lobular invasive carcinoma in 9,3%. The mean diameter of resected tumours measured by pathologists was 38.8 mm. Positive lymph nodes accounted for 62.6% of all tumors. Hormone receptor status was positive in 74% of the cases. Human epidermal growth factor receptor (HER2), was amplified in 34 of 96 tumors. Radiotherapy was delivered in 85% of patients, chemotherapy in 93.6% and hormonal treatment in 65%. The median follow-up was 59 months. The five-year overall survival was 62%. The main prognostic factors on overall survival were the clinical stage (p
Improvement of diagnosis and treatment of breast cancer should increase the incidence of BBC. Management of these cancers aims to control the disease without risking cumulative toxicity.
Clinical trial indentification
Legal entity responsible for the study
Salah Azaiz Institute
All authors have declared no conflicts of interest.